Inducing Factors of Obesity and Weight Management: Research Progress
DOI:
https://doi.org/10.54097/4t09cm88Keywords:
Obesity, weight management, public health.Abstract
The global prevalence of overweight/obesity is rapidly increasing, with approximately 48.9% of adults in China being overweight or obese. With the increase in body mass index, the risk of obesity related complications increases and imposes a heavy economic burden on patients. Overweight/obesity has become a global public health issue. Lifestyle intervention is the cornerstone of obesity management. With the rapid growth of global obesity incidence rate, new weight loss drugs are constantly coming out. Especially the new generation of weight loss drugs, with their significant weight loss efficacy, comprehensive metabolic benefits, and good safety characteristics, bring new hope for weight management in obese patients. Therefore, by combining weight loss measures (i.e. drugs and surgery) with scientific long-term weight management concepts and specific weight loss drug applications. This article aims to update and optimize the confirmation and management of obesity, providing some basic theoretical guidance for weight management of obesity in China and helping patients achieve scientific weight loss.
Downloads
References
[1] Wang Yuepeng, Zang Li, Yiming Mu. The current situation and management of obesity in China. Chinese Journal of Internal Medicine, 2023, 62 (12): 1373 - 1379.
[2] Obesity in Hypertension: The Role of the Expanding Waistline Over the Years and Insights into the Future. Hypertension, 2023, Nov 29.
[3] Zhao Fangye, Zhang Mengjiao, Li Zhenzhen, Dai Jingju, Quan Ying. The influence of color and shape on taste perception. Guangdong Chemical Industry, 2020, 47 (22).
[4] Tang Yicheng, Fan Chunlei. Is taste also a ‘beauty control’? Invention and Innovation, 2022 (04).
[5] Shi Yifan, Pan Changyu, Gao Yan, et al. Efficacy analysis of orlistat in overweight or obese type 2 diabetes patients in China. 2004.
[6] Ryan D.H., Lingvay I., Deanfield J., et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 2024.
[7] Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon-like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022, 23 (3): 521 - 539.
[8] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 384 (11): 989 - 1002.
[9] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023, 389 (24): 2221 - 2232.
[10] Smith SR, Stenlof KS, Greenway FL, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring), 2011, 19 (9): 1796 - 1803.
[11] Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2015, 100 (2): 342 - 362.
[12] Frayling TM, et al. A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science, 2007, 316 (5826): 889 - 894.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
